VentriPoint Diagnostics Ltd. (VPTDF)
VentriPoint Diagnostics Ltd. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.07, down 5.94% on the session, giving a market capitalisation of $13.4M. On trailing twelve-month figures it carries a trailing P/E of -4.87, a net margin of -1778.6%. Its beta of 0.04 implies it has historically moved less than the broad market.
VentriPoint Diagnostics Ltd. (VPTDF) is a medical technology company dedicated to creating and bringing to market diagnostic tools for the global assessment of patients with cardiac conditions. The company's primary offering is the VentriPoint Medical System (VMS), an advanced medical imaging platform. This system, utilizing its VMS+ software, constructs precise three-dimensional representations of a patient's heart chambers by processing echocardiogram and magnetic resonance imaging (MRI) data. It is designed to yield consistent and accurate volumetric and functional measurements, including ejection fraction. Additionally, VentriPoint is actively developing a suite of specialized applications to address a broad spectrum of heart diseases and diverse imaging techniques. This portfolio includes solutions for conditions such as congenital heart defects, pulmonary hypertension, cardiotoxicity observed in oncology patients, and cardiac complications stemming from COVID-19. Established in 2004, the company's headquarters are located in Toronto, Canada.
VentriPoint Diagnostics Ltd. is most often compared with the following Healthcare names: